| Overview |
| bs-12499R |
| APOL4/Apolipoprotein L4 Antibody |
| WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC |
| Human |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human APOL4/Apolipoprotein L4 |
| 1-100/351 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 80832 |
| Secreted |
| APOL IV; ApoL-IV; APOL4; APOL4_HUMAN; Apolipoprotein L IV; Apolipoprotein L-IV; Apolipoprotein L4; APOLIV; CTA 212A2.2; OTTHUMP00000028937. |
| The apolipoprotein L gene family maps to a region on chromosome 22 and encodes six highly homologous proteins designated apoL-I, apoL-II, apoL-III, apoL-IV, apoL-V and apoL-VI, all of which function as components of plasma lipoproteins. ApoL-IV (apolipoprotein L-IV), also known as APOL4, is a 351 amino acid protein that exists as multiple alternatively spliced isoforms, one of which is secreted. Expressed in spleen, placenta, spinal cord, uterus, testis and trachea, apoL-IV is thought to play a role in lipid exchange and transport throughout the body and may be involved in reverse cholesterol transport, specifically from peripheral cells to the liver. Overexpression of apoL-IV is associated with schizophrenia, suggesting that apoL-IV may play a role in the pathogenesis of neural disorders. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
| ICC |
1:100-500 |
Powered by Bioz